A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Laboratory and medical history parameters not within the protocol-defined range.
• •Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
• •Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.
• •Receipt of a live vaccine within 30 days of planned start of study therapy.
• •Active autoimmune disease.
• •Prior treatment with any tumor necrosis factor super family agonist.
• •Known active central nervous system metastases and/or carcinomatous meningitis.
• •Evidence of active, non-infectious pneumonitis or history of interstitial lung disease.
• •Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.